Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanthanum Carbonate Long-term Extension in CKD Hyperphosphatemia
NCT01187628Phase 3Completed
- Sponsor
- Bayer
- Start
- Sep 2010
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of lanthanum carbonate in hyperphosphatemia, sponsored by Bayer. Primary endpoint: Incidence of treatment emergent adverse events. Started Sep 2010; status: completed.
02
Drugs
lanthanum carbonate
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT01187628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01187628.